HUMACYTE INC. - COMMON STOCK

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

28 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

23 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

08 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

04 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

26 9 2024 17:26:25 提供 Nasdaq GlobeNewswire

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

19 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte to Participate at Upcoming Investor Conferences in September

03 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

27 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte Second Quarter 2024 Financial Results and Business Update

13 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024

12 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

09 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

31 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

16 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

01 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

25 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)

17 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte to Present at the Jefferies Global Healthcare Conference

30 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte to Participate at Upcoming Investor Conferences in May

13 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Humacyte First Quarter 2024 Financial Results and Business Update

10 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024

06 5 2024 08:00:00 提供 Nasdaq GlobeNewswire